

To: emlsecretariat@who.int

Subject: Comment in Support of Blinatumomab for Inclusion in the WHO Model List of Essential Medicines for Children

Date: 2 April 2025

Dear WHO Expert Committee,

As a pediatric oncologist, I have seen firsthand the impact of B-cell acute lymphoblastic leukemia in children—particularly in settings where access to innovative therapies is limited. Blinatumomab offers a highly effective, targeted option for these patients and has transformed outcomes in high-income countries.

Its inclusion on the WHO Model List of Essential Medicines for Children would be a critical step toward expanding equitable access to this life-saving therapy in low- and middle-income countries. It would also support integration into national treatment protocols and facilitate procurement mechanisms aligned with WHO's Global Initiative for Childhood Cancer.

I strongly support this application and urge the Committee to approve blinatumomab for inclusion.

Sincerely,

Atsushi Manabe, MD, PhD

Professor and Chairman

Department of Pediatrics

Hokkaido University

Graduate School of Medicine

Kita 15, Nishi 7, Kita-ku, Sapporo, 060-8638, Japan

Phone: +81-11-706-5954

Fax: +81-11-706-7898

E-mail: atmanabe@med.hokudai.ac.jp